Integrating Buprenorphine Treatment into Office-based Practice: a Qualitative Study
- 324 Downloads
Despite the availability and demonstrated effectiveness of office-based buprenorphine maintenance treatment (BMT), the systematic examination of physicians’ attitudes towards this new medical practice has been largely neglected.
To identify facilitators and barriers to the potential or actual implementation of BMT by office-based medical providers.
Qualitative study using individual and group semi-structured interviews.
Twenty-three practicing office-based physicians in New England.
Interviews were audiotaped, transcribed, and entered into a qualitative software program. The transcripts were thematically coded using the constant comparative method by a multidisciplinary team.
Eighty percent of the physicians were white; 55% were women. The mean number of years since graduating medical school was 14 (SD = 10). The primary areas of clinical specialization were internal medicine (50%), infectious disease (20%), and addiction medicine (15%). Physicians identified physician, patient, and logistical factors that would either facilitate or serve as a barrier to their integration of BMT into clinical practice. Physician facilitators included promoting continuity of patient care, positive perceptions of BMT, and viewing BMT as a positive alternative to methadone maintenance. Physician barriers included competing activities, lack of interest, and lack of expertise in addiction treatment. Physicians’ perceptions of patient-related barriers included concerns about confidentiality and cost, and low motivation for treatment. Perceived logistical barriers included lack of remuneration for BMT, limited ancillary support for physicians, not enough time, and a perceived low prevalence of opioid dependence in physicians’ practices.
Addressing physicians’ perceptions of facilitators and barriers to BMT is crucial to supporting the further expansion of BMT into primary care and office-based practices.
KEY WORDSopioid-related disorders qualitative research buprenorphine physicians
- 1.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (text revision). 4th edn. Washington, DC: Author; 2000.Google Scholar
- 9.NIH Consensus Panel. Effective medical treatment of opiate addiction. National Consensus Development Panel of Effective Medical Treatment of Opiate Addiction. 1998;280:1936–43.Google Scholar
- 10.Office of National Drug Control Policy. Policy Paper –Opioid Agonist Treatment. Washington, D.C.: Executive Office of the President, Office of National Drug Control Policy; March, 1999.Google Scholar
- 11.Rettig RA, Yarmolinsky A, eds. Federal Regulation of Methadone Treatment. Washington, DC: Institute of Medicine, National Academy Press; 1995.Google Scholar
- 17.O’Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100–05.CrossRefPubMedGoogle Scholar
- 18.Glaser BG, Strauss AL. The Discovery of Grounded Theory: Strategies for Qualitative Research. New York: Aldine Publishing Company; 1967.Google Scholar
- 25.Egan J, Netherland J, Finkelstein R, Fiellin D. Facilitating buprenorphine implementation: The physician Clinical Support System. College on Problems of Drug Dependence Annual Meeting, June 18, 2006, Scottsdale, Arizona.Google Scholar
- 26.Netherland J, Botsko M, Egan J, Saxon A, Cunningham CO, Finkelstein R, Gourevitch MN, Renner J, Sohler NL, Sullivan LE, Weiss L, Fiellin D, (in press). Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat.Google Scholar